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Background: Stimulant use among individuals with opioid use disorder has recently
increased, driven by changes in drug distribution channels. However, our understanding
of polysubstance use is often limited by a need to provide targeted treatment to a primary
drug of addiction. Yet there is a crucial need to better understand pathways to addiction,
and how the use of multiple substances may differ between populations, as well as
time periods.
Methods: Using a national opioid surveillance system, we analyzed survey data from
new entrants to 124 opioid use disorder treatment centers from 2017 to 2020. Age
of first use was collected for prescription opioids, illicit opioids, prescription stimulants,
crack/cocaine, and methamphetamines. Year of initial use of an opioid or stimulant was
calculated and grouped by 5 year blocs, inclusive of initial use starting from 1991 and
ending in 2020 (n = 6,048).
Results: Lifetime exposure to stimulants was 82.5% among individuals with opioid
use disorder. Mean age of initiation increased for all drugs in 2016–2020, in particular
prescription opioids (22.3 to 31.8). Stimulants were initiating drugs for a substantial
proportion of individuals with opioid use throughout the analyzed time period. Those
initiating opioid/stimulant use from 1991 to 1995 had a mean average of 6.8 years
between first and second drug exposure, which steadily decreased to 1.5 years between
exposures in 2016–2020. Sankey plots depict significantly more drug transitions in those
initiating use from 1991 to 2000 (65.1% had at least two drug transitions) compared
to 2010–2020 (16.0%). Opioid-stimulant use increased over time among racial/ethnic
minorities, sexual minorities, and those with an educational attainment of high school
or less.
Conclusion: These data highlight not only the substantial prevalence of stimulant use
among individuals who develop opioid use disorder, but also the variability through
which pathways of use occur. Prevention and intervention efforts need to take into
account increasing ages of initial drug exposures, demographic shifts in stimulant-using
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populations, and more rapid drug transitions between opioid and stimulants. But at a
broader level, prevention, harm reduction ideology, and addiction medicine needs to
take into account the ubiquity of polysubstance use among individuals with substance
use disorders.
Keywords: opioid use disorder, opioids, stimulants, addiction, polysubstance use

INTRODUCTION

of polysubstance use has been limited, often the result of a need
to provide targeted treatment to a primary drug involved in the
biological underpinnings of addiction. Yet there is a crucial need
to better understand pathways to addiction, and how the use of
multiple substances may differ between populations, as well as
time periods.
Drug markets are no less susceptible to secular changes
than other institutions; indeed, significant disruptions have
occurred in recent years as a result of stricter opioid policies,
reductions in domestic methamphetamine laboratories, changes
in drug market supplies, and the COVID-19 pandemic (28, 30).
However, the extent to which these interdictions have influenced
polysubstance use is still largely unknown. Retrospective analyses
have been used to demonstrate shifts in opioid pathways,
primarily national trends suggesting shifts from prescription
opioids to heroin. The purpose of the present study was to
conduct a retrospective analysis of stimulant use over the past
30 years to investigate the prevalence of stimulant use, better
understand pathways that link opioid and stimulant use, and
ascertain potential shifts in opioid and stimulant use over time.

In 2020, the United States reported the greatest number of
overdose fatalities on record, over 93,000 (1). Primarily driven
by overdoses involving opioids, this surge occurred amidst a
pandemic that resulted in interruptions to addiction medicine
and social support (2–5). Over the past two decades, the opioid
crisis has led to renewed understandings of addiction prevention
and treatment, with a number of federal, state and local policies
implemented focusing on mitigating supply-side forces such as
guidelines and legislation targeting prescription practices (6,
7), prescription drug monitoring programs (8, 9), and abusedeterrent formulations (10, 11). As the crisis has persisted, recent
efforts have been made to better understand the demand-side of
addiction (12–15); not only by understanding motivations tied
to co-morbid conditions such as mental health and chronic pain
(16–18), but also the unique role that polysubstance use (i.e., use
of multiple classes of substances) plays in addiction pathways.
Evidence suggests that polysubstance use is widely prevalent
among individuals with addiction, particularly those with opioid
use disorder (19–21).
In recent years, the use of illicit psychostimulants such as
methamphetamine and cocaine have increased, particularly
among those using opioids (22–27). Much of this shift is due
to changes in market supply forces such as production and
distribution. In the early 2000s, efforts by law enforcement
agencies focused heavily on halting domestic methamphetamine
production, so much so that drug seizures from domestic
methamphetamine laboratories reached its lowest point
in 2019 (28). However, as localized methamphetamine
production decreased, there was a proliferation of synthetically
produced substances such as fentanyl from foreign countries.
Methamphetamine supply in the United States is now primarily
driven by an influx of manufacturers from Latin and South
America (28).
As a result of these new and prolific distribution channels,
reports of psychostimulant use and overdose have increased
markedly in recent years (22–27). These increases are partially
attributable to an increased and cost-efficient supply, and
identifiable or unidentifiable lacing of one drug with another
(e.g., fentanyl laced cocaine, methamphetamine laced fentanyl).
However, other motivations for the use of psychostimulants
among individuals using opioids have been reported, including:
self-management of withdrawal symptoms, particularly if opioids
are not available; attaining a synergistic high; and to balance
one’s self out throughout the day with cyclical use of opioids and
stimulants (29).
Although opioids were the largest contributor to overdose
fatalities, the use of methamphetamine and cocaine has not been
absent throughout the opioid crisis. However, our understanding
Frontiers in Psychiatry | www.frontiersin.org

MATERIALS AND METHODS
Sample Development
All participants in this study were obtained through the
Survey of Key Informants’ Patients (SKIP) Program. Briefly,
the SKIP Program is an opioid surveillance program that
utilizes a serial cross-sectional survey, and is nested within the
broader Researched Abuse, Diversion and Addiction-Related
Surveillance (RADARS R ) System. Treatment centers from across
the country are selected based on their ability to treat opioid
use disorder, and their willingness to participate in an ongoing
study regarding opioid use disorder and its correlates. Following
verbal consent to participate, each of these treatment centers (i.e.,
“key informants”) is supplied with, anonymous paper surveys,
each ascribed a unique identifier, and directed to provide one
survey to persons (i.e., “patients”) 18 years or older who are
newly entering the facility with a primary diagnosis of an opioid
use disorder, as defined by DSM-IV or V criteria (depending on
the time of survey completion). Patients (hereafter, respondents)
who agree to participate are given a $20 Wal-Mart gift card for
completion of the survey, along with a self-addressed stamped
envelope to mail the survey directly to Washington University in
St. Louis (WUSTL). All protocols were approved by the WUSTL
Institutional Review Board.
The present analysis was developed using data from 7,019
respondents who had entered any one of the 124 regionally
distributed treatment centers between 2Q2017 and 4Q2020.
2
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Opioid and Stimulant Use Over Time

the order of use of more than one drug in a single year could
not be discerned (n = 883). A comparison of those included
vs. excluded for analyses are included in Supplementary Table 1.
There were no significant differences between those who initiated
use with a single vs. multiple substances in the year of initial
drug exposure, with the exception of mean age, which differed
by less than a year (multiple = 31.6 vs. single = 32.4), and mean
age of initiation, which was slightly, but significantly higher for
those excluded form analyses (multiple = 18.4 vs. single = 16.6).
For those that remained, drugs were ordered by their age of first
use and then the differences between these ages were averaged
to determine number of years between drug transitions (i.e., first
drug to second drug, second drug to third drug, etc.).
Sankey plots were then created, inclusive of participants who
(1) reported initiation and transitions to a single substance and
(2) those who initiated substance use between 1991 and 2000
or between 2011 and 2020. Participants were then exclusively
stratified into one of two groups based on period of first substance
initiation: group 1: 1992–2000 and group 2: 2011–2020. Counts
of those transitioning from substance-to-substance were then
used to construct a Sankey plot for each period. The years from
2001–2010 were excluded from these analyses in order to provide
a more distinct temporal comparison of opioid and stimulant
drug transitions.

Given the overlap of some of these drugs, both chemically and
in illicit drug use, drug strata were delineated by having ever
used opioids—consisting of two groups, namely prescription
opioids and illicit opioids (i.e., heroin or illicit fentanyl)—and
stimulants—consisting of prescription stimulants, crack/cocaine,
or methamphetamine. Age of first use was collected for each
drug of interest, which acted as a proxy for lifetime use.
Prevalence estimates were subsequently calculated. However,
with a respondent age range of 65 years, we sought to account
for the effect that one’s length of lifetime drug use (that is, the
difference between age at treatment entry and age at first drug
exposure) may have on these estimates, as well as the age of
first drug exposure. Utilizing Random Iterative Method (RIM)
weighting in IBM SPSS Statistics v28, the weighted adjusted
prevalence estimates were equivalent to unadjusted rates.
In connection with the sample-wide variance in length of
lifetime drug use, and to attend more closely to drug use
patterns that have occurred in recent years, our sample was
subsequently restricted to individuals whose first use of any
drug began within the last 30 years (i.e., no earlier than 1991),
thereby removing 14.4% of the original sample for an analytic
sample size (N) of 6,048. Age of first use was used to calculate
year of initial drug exposure, which was defined as the earliest
year for which one of the five drugs of interest was used by a
respondent. Additionally, to illustrate changes in drug use over
time, quinquennial groupings were established and defined as the
year wherein respondents first used their first drug, whatever the
drug may be. In accord with this definition, prevalence estimates,
mean ages, and number/types of drugs are all reported as a
function of the 5 year bloc within which drug use was initiated.
Following this sketch of initial drug exposure (again,
irrespective of drug), respondents were categorized into nonexclusive, drug-specific groupings based on which drug(s) they
had used first. Temporal comparisons of the mean age of
exposure for each are reported.

RESULTS
Demographic Characteristics
Table 1 describes the demographic profiles of individuals with
opioid use disorder who had lifetime exposure to stimulants by
5 year bloc. The proportion of individuals with opioid-stimulant
use significantly decreased among females (65.3 to 45.5%, p <
0.001), urban residents (57.7 to 51.5%, p < 0.001), and those
with an educational attainment of some college (41.2 to 32.4%,
p < 0.001). Conversely, the proportion of opioid-stimulant users
significantly increased among racial/ethnic minorities (20.3 to
36.2%, p < 0.001), sexual minorities (11.5 to 27.7%, p = 0.001),
suburban residents (23.1% to 24.2%, p = 0.002), residents of the
Western region of the United States (17.2 to 31.9%, p < 0.001),
and those with an educational attainment of high school or less
(54.5 to 58.8%, p < 0.001). Lifetime history of prior treatment
episodes was endorsed by the majority of respondents in each
5 year bloc, but significantly decreased in the proportion, from
87.6 to 62.3% (p < 0.001). Mean age of respondents at the time of
survey completion decreased from 40.5 to 32.3 (p < 0.001), while
mean age of initial drug exposure increased from 15.4 to 25.6 (p
< 0.001).

Opioid and Stimulant Pathways and
Demographics Over Time
To examine polysubstance use pathways and to evaluate the
general influence time has had on drug transitions, we further
restricted our sample to be constituted solely of individuals who
had ever used opioids and stimulants (n = 4,935, 81.6% of
N). Among these, years to a drug/drug class transition were
calculated based on the respondent’s age upon initiating any of
the respective drugs, whichever came first, and the age at which
a change in drug/drug class was made. Drug-drug transitions
included the difference among first using any of the five drug
groups; class-class transitions included the difference among first
using either of the two drug classes. Protracted comparison
of these individuals’ demographic characteristics and univariate
statistics were developed as well.

Stimulant Use Among Individuals With
Opioid Use Disorder
As shown in Figure 1, lifetime exposure to stimulants was
very high among this sample of individuals with opioid
use disorder, with 82.4% reporting the use of prescription
stimulants, crack/cocaine or methamphetamine, after adjusting
for time since initial drug exposure to an opioid or stimulant.
Crack/cocaine had the highest adjusted rate of lifetime

Opioid and Stimulant Drug Transitions
In order to observe temporal differences in ordered pathways
of substance use, those who initiated more than one drug in a
single year were excluded from the baseline analysis sample as

Frontiers in Psychiatry | www.frontiersin.org
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1991–1995 (n = 680)

1996–2000 (n = 1,044)

2001–2005 (n = 1,399)

2006–2010 (n = 1,193)

2011–2015 (n = 550)

2016–2020 (n = 69)

Sig. (X2 )

Ellis et al.
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TABLE 1 | Demographic characteristics of individuals with opioid use disorder with lifetime exposure to stimulant drugs, grouped by year of initial drug exposure.

Demographics
Female

441

65.3%

620

59.7%

802

57.8%

662

55.8%

296

54.1%

30

45.5%

<0.001

Racial/ethnic minority

138

20.3%

205

19.6%

227

16.2%

236

19.8%

160

29.1%

25

36.2%

<0.001

Sexual minority

38

11.5%

53

11.0%

78

11.3%

77

13.4%

56

18.1%

13

27.7%

0.001

Mean age (SD)

40.5 (5.9)

36.2 (5.4)

32.0 (5.2)

28.0 (5.1)

25.7 (6.2)

32.3 (7.2)

<0.001

Mean age of initial exposure (SD)

15.4 (5.6)

15.9 (5.2)

16.6 (4.9)

17.4 (4.9)

19.5 (6.2)

25.6 (10)

<0.001

Urbanicity
Urban

382

57.7%

530

52.0%

668

48.8%

540

46.6%

236

43.7%

34

51.5%

<0.001

Suburban

153

23.1%

250

24.5%

380

27.8%

351

30.3%

167

30.9%

16

24.2%

0.002

Rural

127

19.2%

240

23.5%

320

23.4%

267

23.1%

137

25.4%

16

24.2%

0.186

Regionality
West

117

17.2%

168

16.1%

261

18.7%

234

19.6%

135

24.5%

22

31.9%

<0.001

Midwest

187

27.5%

270

25.9%

369

26.4%

325

27.2%

131

23.8%

17

24.6%

0.070

Northeast

76

11.2%

139

13.3%

214

15.3%

172

14.4%

66

12.0%

4

5.8%

0.030

South

300

44.1%

467

44.7%

555

39.7%

462

38.7%

218

39.6%

26

37.7%

0.023

None

237

41.0%

341

38.5%

491

40.5%

376

36.4%

167

34.7%

19

33.3%

0.104

Covered under another individual

16

2.8%

26

2.9%

28

2.3%

70

6.8%

76

15.8%

8

14.0%

<0.001

Medicare/Medicaid

282

48.8%

440

49.7%

604

49.9%

512

49.6%

206

42.8%

24

42.1%

0.011

Private

33

5.7%

58

6.6%

69

5.7%

67

6.5%

28

5.8%

6

10.5%

0.691

Healthcare coverage

4

VA/Military healthcare

10

1.7%

20

2.3%

19

1.6%

8

0.8%

4

0.8%

0

0.0%

0.075

Any healthcare coverage

341

59.0%

544

61.5%

720

59.5%

657

63.6%

314

65.3%

38

66.7%

0.104

High school or less

364

54.5%

561

54.2%

789

56.8%

734

62.0%

374

68.1%

40

58.8%

<0.001

Some college

275

41.2%

420

40.5%

534

38.5%

403

34.0%

166

30.2%

22

32.4%

<0.001

Bachelor’s or higher

29

4.3%

55

5.3%

65

4.7%

47

4.0%

9

1.6%

6

8.8%

0.006

Prior OUD treatment episodes

595

87.6%

888

85.1%

1,170

83.8%

939

78.8%

405

73.6%

43

62.3%

<0.001

Educational attainment

Stimulants and Opioid Use Disorder
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FIGURE 1 | Prevalence of lifetime exposure to opioid and stimulants among individuals with opioid use disorder (n = 7,109), adjusted for age of initial drug exposure
and time since year of initial drug exposure.

Initial Drug Exposure

use (68.6%), followed by methamphetamines (63.1%) and
prescription stimulants (50.6%).
Respondents were categorized by the year of initial drug
exposure to either an opioid or a stimulant and grouped
into 5 year blocs across the past 30 years, from 1991 to
2020. Figure 2 depicts lifetime use of opioid and stimulant
categories by respondent’s year of initial drug exposure. Of
those who initiated use from 1991 to 2010, lifetime use of
all three stimulant categories were reported by over half the
sample; 54.0–58.5% for prescription stimulants, 68.3–68.2% for
methamphetamines, and 80.3–66.0% for crack/cocaine. These
rates were lower in more recent years with just 5.1% exposed
to prescription stimulants, and 12–13% to crack/cocaine and
methamphetamines, by 2016–2020.
Figure 3 shows that the mean age of initiation for all opioid
and stimulant classes ever used stayed relatively stable from 1991
to 2015, but significantly increased in 2016–2020. Age of first
exposure to prescription opioids saw the greatest increase, from
a mean age of initiation of 22.3 in those first exposed in 2011–
2015, to 31.8 for those initiating use in 2016–2020. Similarly, but
to a lesser extent, illicit opioid initiation rose from 22.8 to 28.2
years old, crack/cocaine from 21.3 to 26.9 years old, prescription
stimulants from 18.8 to 22.3 years old, and methamphetamines
from 20.4 to 23.7 years old.

Frontiers in Psychiatry | www.frontiersin.org

Figure 4 shows the number of drugs respondents were exposed
to in the year of initial drug exposure to an opioid (prescription
opioids or illicit opioids) and/or a stimulant (prescription
stimulants, crack/cocaine, or methamphetamines). Respondents
primarily reported the use of a single substance in the year of
initial drug exposure, although this decreased from 83.2% in
1991–1995 to 73.8% in 2011–2015, and finally increasing back
up to 80.3% in 2016–2020. The specific drugs initiated in the
year of initial drug exposure are shown in Figure 5, taking into
account the use of multiple drugs in a single year (i.e., totals
may equal over 100%). The use of prescription opioids as an
initiating drug increased from 36.4% in 1991–1995 to 74.9% in
2016–2020. Illicit opioids as an initiating drug increased from
a low of 8.7% in 2001–2005 to 32.8% in 2016–2020. Stimulants
were initiating drugs for a substantial proportion of individuals
with opioid use disorder in the 1990s and early 2000s, decreasing
significantly to the point where <10% reported initiating use with
each stimulant class: prescription stimulant as initiating drug
decreased from 26.7 to 2.8%, crack/cocaine from 23.3 to 8.0%,
and methamphetamine from 20.6 to 9.4%.
Figure 6 outlines the mean age of only one’s initial drug
of exposure by year of exposure. Similar to Figure 3, the
mean age of those initiating their opioid/stimulant use with
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FIGURE 2 | Prevalence of lifetime exposure to opioids and stimulants grouped by year of initial drug exposure among individuals with opioid use disorder.

FIGURE 3 | Mean age of first use of opioids (A) and stimulants (B) among individuals with opioid use disorder by year of drug exposure.

stimulant initiators, whose mean age grew from 10.8 in
1991–1995 to 23.5 in 2016–2020. This was followed by
crack/cocaine (18.4 to 27.8), and methamphetamines (15.9 to
21.8).

prescription opioids increased from 17.13 in 1991–1995 to
32.1 in 2016–2020, and illicit opioid initiators had a mean
age increase from 21.3 to 29.3. For those who initiated use
with stimulants, the largest increase was among prescription

Frontiers in Psychiatry | www.frontiersin.org
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FIGURE 4 | Number of drugs (opioids and/or stimulants) used in the year of initial drug exposure.

Drug Transitions and Pathways

decreasing time between drug transitions over each 5 year bloc
was consistent regardless of which drug was the initial drug of
exposure. This trend also applied to subsequent drug transitions.
Of those who had subsequent drug transitions across the five
studied drugs, drug transition times decreased slightly after the
initial drug transition, but were still relatively similar within
their respective 5 year bloc (Figure 9). Of those who initiated
use in 1991–1995, mean drug transitions took 5–6 years. This
steadily decreased to where, in 2011–2015 transition times were
1–2 years. Initiators in 2016–2020 had only two drug transitions
by the time of data analysis, with transition time of 1.5 years.
Figure 10 provides a comparative overview of drug transitions
from 1991 to 2000 and 2010 to 2020 in order to demonstrate
temporal shifts in drug transition pathways. As can be seen, there
was significant variability in pathways from 1991 to 2000, with
88.8% or respondents having one drug transition, 65.1% with
two drug transitions, 39.1% having three drug transitions, and
15.4% having four drug transitions; significantly different from
41.8, 16.0, 5.2, and 1.5%, respectively, in those who initiated use
from 2010 to 2020. Notably, those initiating use in the last decade
primarily did so through prescription opioids, compared to
initiates from 1991 to 2000, who had roughly equal proportions
of initiation through stimulants and prescription opioids. Illicit
opioids were also more common in later stages of use from 1992
to 2000, compared to earlier stages in 2010–2020.

Using age of initial exposure, the mean number of years was
calculated between a respondent’s first use of an opioid and
subsequent first use of a stimulant, and vice-versa, depending
on the order of use (Figure 7). In 1991–1995, those initiating
use of an opioid subsequently initiated use of a stimulant on
average, 4 years later, while those initiating use of a stimulant
subsequently initiated use of an opioid 7.4 years later. The mean
number of years between exposures of opioids and stimulants
decreased for both ordered types of respondents over time,
although the decrease was more drastic for those transitioning
from stimulants to opioids. Those initiating use in 2006–2020 had
similar transition times regardless of the pathway, 2.2 years, and
these similarly decreased to 1.3 years in 2011–2015 and 0.3–0.4
years in 2016–2020.
Excluding individuals who used multiple drugs in a single
year to reduce data noise and uncertainty of order of use, 76.7%
of respondents had at least one drug transition (i.e., initiated
use of another drug in a subsequent year) among the five
studied drug categories. Figure 8 shows the mean number of
years between initial drug exposure and the first drug transition.
Those initiating use from 1991 to 1995 had a mean average
of 6.8 years between first and second drug exposure. However,
this steadily decreased over time to 1.5 years between exposures
among 2016–2020 initiators. As shown in the figure, this trend of

Frontiers in Psychiatry | www.frontiersin.org
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FIGURE 5 | Types of opioids and stimulants used in the year of initial drug exposure. Total percentage may exceed 100% as multiple drugs may have been used in
the year of initial drug exposure.

FIGURE 6 | Mean age of first use of opioids or stimulants when used as the initial drug of exposure, grouped by year of initial drug exposure.

DISCUSSION

disorder. Unsurprisingly, this retrospective analysis indicates
that stimulant exposure grows in prevalence the longer time
has elapsed since initial drug exposure; greater lengths of time
likely provide greater opportunities for lifetime exposure. This

These data suggest that exposure to stimulant drugs is
extremely common among individuals who develop opioid use

Frontiers in Psychiatry | www.frontiersin.org
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FIGURE 7 | Mean number of years between first use of an opioid and first use of a stimulant, or first use of a stimulant and first use of opioid, grouped by year of initial
drug exposure.

appears to hold true not just for illicit stimulant drugs, but
for prescription stimulants as well. However, there were other
notable trends visible over the past 30 years.
Most notably, the time elapsed between exposures of differing
drug categories significantly decreased over time. This was
visible in both class-class pathways (i.e., opioid-to-stimulant and
stimulant-to-opioid) and drug-drug pathways, irrespective of
the initiation drug or number of drug transitions. All showed
a steady decline, with an average of 5 years between drug
exposures in the early 1990s, to a year or less in 2016–2020.
The reasons behind this trend likely involves a multitude of
factors. First, market forces significantly have changed in the
past 30 years. In the early 1990s, the prescription opioid
crisis was in its infancy and methamphetamine was often
relegated to rural areas through domestic production, likely
making access to these drugs scarcer than in ensuing years.
As the prescription opioid crisis broadened, subsequent drug
production shifted first to cheaper heroin and crack/cocaine,
and then to even more cost-efficient synthetic drugs such as
fentanyl and methamphetamine, produced through precursors
obtained from one foreign country to be produced in another,
eventually distributed in the United States (28). As these markets
have grown, access and availability have responded accordingly.
There is also likely some measure of compensatory use of other

Frontiers in Psychiatry | www.frontiersin.org

drugs when supplies of a preferred drug are limited. Shifts to
heroin and methamphetamine have been observed when access
to prescription opioids has become more limited as a result
of supply-side policies targeting reduction in their distribution
(29, 31). It is also possible that exposure has been complicated
in recent years by adulterated drugs such as methamphetaminelaced fentanyl or fentanyl-laced cocaine. Current prevention and
harm reduction efforts need to take into account evidence that
suggests transitions from one drug to another are now occurring
at a rapid rate, and will likely increase the rapidity with which
oral use may graduate to non-oral use. Indeed, comprehensive
care would be amiss if it did not incorporate these factors
into the current regimen of naloxone promotion, pre-exposure
prophylaxis, needle exchanges and educational efforts.
Prevention and intervention efforts should also take into
account the shifting ages at which initiation of use has changed
in recent years. Prescription opioid initiation saw the largest
increase in age of exposure, increasing from late teens-early
twenties to early thirties. For those whose first exposure to an
opioid or stimulant was through prescription stimulants, the
mean age rose from 10 years old to 23.5 years. These dramatic
shifts may be the result of a greater awareness of the potential
harms or consequences of these medications among healthcare
providers and systems, leading to reductions of prescriptions of
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FIGURE 8 | Mean number of years between initial and second drug exposure, grouped by year of initial drug exposure. Bars reflect mean number of years between
transitions for all drugs, with lines representing mean number of years between transitions between specific initial drugs and a secondary drug.

of initiators through opioids, both prescription and illicit. To
the latter point, a third of all initiators in 2016–2020 used illicit
opioids, further reinforcing the broadening of illicit opioids as
one’s first experience with opioids, presenting significant dangers
to opioid naïve individuals who may be inexperienced in dosing,
titration and the presence of admixtures such as fentanyl-laced
heroin. In terms of stimulants, since this is a sample of individuals
who develop opioid use disorder, it is possible that those who
initiated drug use through stimulants have not yet graduated
to opioids, and thus have yet to be captured in this sample,
leading to lower rates of stimulant initiation than previous years.
However, the mean time lapse between transitions would counter
this argument as transitions to other drugs are now occurring
at a rapid rate. The important point here is that, while not
all individuals with opioid use disorder used stimulants, it is
notable that throughout the opioid crisis, a substantial number
of individuals were exposed to stimulants prior to opioids. This
further underscores the complicated nature of polysubstance use.
Indeed, the transition plots demonstrate the significant variability
of pathways between opioids and stimulants, particularly as time
has progressed. Transition plots from 1991 to 2000 showed
significant exposure to multiple drugs, but there were few clearcut pathways that would suggest a commonality of drug pathways
or “gateway” drugs, at least within the sphere of stimulants

opioids and stimulants among younger individuals. This may
have resulted in subsequent increases in age of exposure for
other drugs that followed initial exposure through a prescription.
However, there were significant increases also observed in those
whose first opioid or stimulant drug was an illicit one. While
further research is needed to understand these shifts, it is
possible that prevention and educational efforts targeting young
adults have had an effect, and further efforts are needed to
target those in their late twenties or early thirties. This is
particularly notable in light of the recent pandemic, as well as
earlier recessions in the time period of analysis, which caused
social and economic upheaval that may disproportionately have
impacted individuals in these age groups who are often early
in their careers and relationships. In fact, this may help explain
other demographic shifts in stimulant use that occurred over
time, particularly among those that are often at higher risk of
being impacted economically during times of national distress,
racial/ethnic minorities, sexual minorities, and those with lower
educational attainment.
These data also suggest that opioid and stimulant use occurs
across a variety of pathways. However, there do appear to have
been shifts in these pathways over time. Interestingly, despite
the focus of federal and state policies on mitigating the opioid
epidemic in the 2010s, 2016–2020 had the greatest proportion
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FIGURE 9 | Mean number of years between drug exposures, grouped by year of initial drug exposure.

FIGURE 10 | Sankey plots of ordered drug transitions by decade of initial drug exposure: (A) 1991–2000, n = 1,079; (B) 2010–2020, n = 749.
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despite recent increases in national trends of illicit stimulant
use, they have played a significant contributing role throughout
from the beginning of the opioid crisis. Recent demographic
shifts indicate that those initiating use of opioids and stimulants
today may be different than those from years past, particularly
in young adults of a greater age. Additionally, transitions to
other drugs is occurring at a far faster rate than previously seen.
Prevention and intervention efforts need to take these shifts
into account. But at a broader level, preventative educational
and screening efforts, harm reduction ideology, and treatment
through addiction medicine needs to take into account the
ubiquity of polysubstance use among individuals with substance
use disorders.

and opioids. Pathways were somewhat easier to discern in more
recent years. From 2010 to 2020, the majority of initiators started
with prescription opioids and moved to illicit opioids, while
those who initiated use with stimulants next went to prescription
opioids. This further underscores the need for continued efforts
to mitigate diversion of prescription opioids and safe prescribing
practices. Despite more rapid transition times in recent years,
it is possible, and may be more likely given recent increases
in methamphetamine and cocaine use, these individuals will
engage in polysubstance use inclusive of a wider variety of drugs
as years progress. Treatment for opioid use disorder needs to
take into account polysubstance use, viewing addiction as a
broader condition that encompasses the use of multiple drugs,
rather than a condition isolated to a single, primary drug of
use. This includes a deeper understanding of motivations for the
use of different classes of substances, particularly the potential
for self-management of addiction to one drug with another,
and perceptions that the use of other substance outside of
one’s primary drug of addiction are conceptually different when
considering one’s addiction.
There are several limitations that are important to note
when interpreting these data. First, these data are reflective of
individuals entering a treatment program for opioid use disorder
within the past 10 years, and thus may reflect a population for
which treatment retention and success is lower than average, as
well as potentially including a measure of survivor bias, wherein
a certain proportion likely succumbed to an overdose or drugassociated fatality. Second, our data are limited in more recent
years by a “treatment-gap” bias, wherein there are likely initiators
in 2016–2020 whose use has not progressed to the point where
treatment is sought, thus potentially reducing generalizability
to recreational or non-problematic individuals using opioids. In
addition, it is possible that there are significant differences in the
time and severity in the escalation of use that drives treatmentseeking behavior, which may limit direct comparisons between
5 year blocs. Third, our data assess lifetime exposure and does
not assess duration or severity of use of these drugs, or the use of
other substances that may have impacted pathways of stimulant
and opioid use such as tobacco, alcohol, marijuana or other
substances. Finally, and most notably, these data assess age of
exposure, which does not take into account the motivations or
reasons behind use. While less applicable to the illicit drugs, it
is likely that first exposure to prescription opioids or stimulants
were through therapeutic channels, for therapeutic purposes,
and therefore, may not be representative of problematic use.
However, therapeutic channels as initial exposures to opioids
and stimulants have been shown to increase of subsequent
problematic use.
These data highlight not only the substantial prevalence
of stimulant use among individuals who develop opioid use
disorder, but also that opioid and stimulant polysubstance use
develops through a number of pathways, often a result of both
supply (i.e., accessibility) and demand (i.e., motivations for use)
side factors. Importantly, stimulant use played a significant
introductory role to substance use prior to opioid initiation, and
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